Brief: Xbrane Biopharma Submits BLA To FDA For Lucentis Biosimilar Candidate
30/04/2026 07:07
April 30 (Reuters) - Xbrane Biopharma AB XBRANE.ST: SUBMITS BLA TO FDA FOR LUCENTIS BIOSIMILAR CANDIDATE Source text: ID:nMFN79W1Rg Further company coverage: XBRANE.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Xbrane Biopharma AB
See all newsBrief: Xbrane Biopharma, JOINN Biologics US Partner To Develop Xdarzane
Brief: Xbrane Gets FDA BsUFA Review Date
Brief: Xbrane, Partner Intas Agree On Revised Financing Arrangement
Brief: Venture Valuation Provides External Valuation Of Xdivane Program
Brief: Xbrane Biopharma Submits BLA To FDA For Lucentis Biosimilar Candidate